Arcutis Biotherapeutics (ARQT) News Today $14.86 +1.29 (+9.51%) (As of 12/17/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Franklin Resources Inc. Decreases Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Franklin Resources Inc. decreased its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 4.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,250,418 shares of the company's sDecember 18 at 4:55 AM | marketbeat.comShort Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Decreases By 6.0%December 18 at 4:23 AM | americanbankingnews.comArcutis Biotherapeutics Target of Unusually High Options Trading (NASDAQ:ARQT)December 18 at 1:35 AM | americanbankingnews.comArcutis Biotherapeutics submits sNDA for ZORYVE cream to FDADecember 17 at 7:03 PM | markets.businessinsider.comTraders Buy High Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT)Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock traders purchased 21,719 call options on the company. This represents an increase of approximately 1,193% compared to the typical volume of 1,680 call options.December 17 at 1:26 PM | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Hits New 52-Week High - Here's WhyArcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 12-Month High - Here's WhyDecember 16 at 5:15 PM | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Sees Large Drop in Short InterestArcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large decrease in short interest in the month of November. As of November 30th, there was short interest totalling 23,530,000 shares, a decrease of 6.0% from the November 15th total of 25,020,000 shares. Based on an average daily volume of 1,990,000 shares, the short-interest ratio is currently 11.8 days.December 16 at 8:50 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Arcutis Biotherapeutics (ARQT) and Warby Parker (WRBY)December 16 at 7:09 AM | markets.businessinsider.comArcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 4.8% - Still a Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Trading 4.8% Higher - Still a Buy?December 13, 2024 | marketbeat.comPoint72 Asset Management L.P. Makes New $2.27 Million Investment in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Point72 Asset Management L.P. acquired a new stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 244,386 shares of the company's stock, valued at approDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Sells 75,737 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Jacobs Levy Equity Management Inc. reduced its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 43.1% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 100,172 shares of the company's stock after selDecember 9, 2024 | marketbeat.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)December 6, 2024 | globenewswire.comHoward G. Welgus Sells 10,000 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockDecember 4, 2024 | insidertrades.comShort Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Drops By 9.9%Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) was the recipient of a large decline in short interest in November. As of November 15th, there was short interest totalling 25,020,000 shares, a decline of 9.9% from the October 31st total of 27,760,000 shares. Based on an average trading volume of 1,950,000 shares, the short-interest ratio is currently 12.8 days.December 1, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Purchased by Algert Global LLCAlgert Global LLC increased its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 595.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 72,480 shares of the company's stock afterNovember 30, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week High - Time to Buy?Arcutis Biotherapeutics (NASDAQ:ARQT) Sets New 52-Week High - Time to Buy?November 29, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by Suvretta Capital Management LLCSuvretta Capital Management LLC raised its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 7.2% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,721,511 shares of thNovember 29, 2024 | marketbeat.comRubric Capital Management LP Has $101.99 Million Stock Position in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)Rubric Capital Management LP lifted its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 11.7% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,966,672 shares of the company's stock after purchasing an additional 1,150,00November 27, 2024 | marketbeat.comPatrick Burnett Sells 16,023 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockNovember 27, 2024 | insidertrades.comArcutis Biotherapeutics: Resilient Performance and Growth Potential Amidst Short-Term FluctuationsNovember 25, 2024 | markets.businessinsider.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Shares Acquired by Jennison Associates LLCJennison Associates LLC boosted its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 0.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 11,663,497 shares of the coNovember 21, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells $17,182.00 in StockNovember 20, 2024 | insidertrades.comStrong Prescription Growth and Competitive Advantage Drive Buy Rating for Arcutis BiotherapeuticsNovember 19, 2024 | markets.businessinsider.comArcutis Biotherapeutics: What Lies AheadNovember 18, 2024 | seekingalpha.comArcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up?November 15, 2024 | seekingalpha.comTerrie Curran Sells 8,687 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockNovember 14, 2024 | insidertrades.comArcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by GlamourNovember 14, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Arcutis Biotherapeutics (ARQT)November 12, 2024 | markets.businessinsider.comGSA Capital Partners LLP Purchases 208,599 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)GSA Capital Partners LLP increased its holdings in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 730.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 237,174 shares of the company's stock after pNovember 12, 2024 | marketbeat.comArcutis Biotherapeutics: Strong Financial Outlook and Strategic Growth Justify Buy Rating and $19 Price TargetNovember 9, 2024 | markets.businessinsider.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comArcutis Biotherapeutics Reports Strong Q3 2024 ResultsNovember 8, 2024 | markets.businessinsider.comArcutis Biotherapeutics: Strong Q3 Performance and Strategic Growth Drive Buy RatingNovember 8, 2024 | markets.businessinsider.comArcutis Biotherapeutics Inc (ARQT) Q3 2024 Earnings Call Highlights: Robust Growth and ...November 8, 2024 | finance.yahoo.comArcutis Biotherapeutics (NASDAQ:ARQT) Receives Buy Rating from Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $18.00 target price on shares of Arcutis Biotherapeutics in a research note on Thursday.November 7, 2024 | marketbeat.comArcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call TranscriptNovember 7, 2024 | seekingalpha.comArcutis Biotherapeutics: Strong Commercial Execution and Strategic Growth Initiatives Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comArcutis Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | globenewswire.comEarnings To Watch: Arcutis Biotherapeutics Inc (ARQT) Reports Q3 2024 ResultNovember 6, 2024 | finance.yahoo.comMasaru Matsuda Sells 5,015 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) StockNovember 6, 2024 | insidertrades.comArcutis Biotherapeutics: Resilient Growth and Market Penetration Drive Buy RatingNovember 5, 2024 | markets.businessinsider.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 4, 2024 | globenewswire.comabrdn plc Boosts Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)abrdn plc increased its holdings in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 223.8% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 482,074 shares of the company's stock after acquiringNovember 4, 2024 | marketbeat.comArcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Up 8.7% - Here's What HappenedArcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 8.7% - Should You Buy?November 1, 2024 | marketbeat.comAMI Asset Management Corp Buys 59,487 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)AMI Asset Management Corp lifted its stake in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 36.2% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 223,681 shares ofOctober 30, 2024 | marketbeat.comArcutis Biotherapeutics announces new patient-reported data on ZORYVEOctober 24, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Arcutis Biotherapeutics Amid Temporary Challenges and Strong Zoryve Sales ForecastOctober 23, 2024 | markets.businessinsider.comArcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor ConferenceOctober 23, 2024 | globenewswire.comHealth Canada approves Arcutis’ ZORYVE foam for seborrheic dermatitisOctober 22, 2024 | finance.yahoo.comArcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Average Recommendation of "Moderate Buy" from AnalystsShares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the stock, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and fOctober 22, 2024 | marketbeat.com Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s Secret Manhattan Project (Ad)On January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just spent six months investigating this...and what I found is shocking. Click here and I’ll show you exactly how to position your money ARQT Media Mentions By Week ARQT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ARQT News Sentiment▼0.630.71▲Average Medical News Sentiment ARQT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ARQT Articles This Week▼95▲ARQT Articles Average Week Get Arcutis Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARQT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LEGN News Today NUVL News Today BPMC News Today ELAN News Today CYTK News Today TGTX News Today VKTX News Today BBIO News Today CRNX News Today KRYS News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ARQT) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersTrump’s Secret Manhattan ProjectOn January 20, a whole new Manhattan Project is set to begin: Trump’s Manhattan Project. Folks, I just s...Banyan Hill Publishing | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
